重磅BD频出叠加业绩高增，港股通创新药ETF易方达(159316)标的指数涨近3%

Group 1 - The Hong Kong pharmaceutical sector showed strong performance on February 10, with the Hang Seng Hong Kong Stock Connect Innovative Drug Index rising by 2.7% and the CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index increasing by 2.5% [1] - The rebound in the innovative drug sector is likely driven by a surge in business development (BD) transactions and high growth in earnings forecasts [1] - Significant collaborations have been established, including a record-breaking $18.5 billion partnership between CSPC Pharmaceutical and AstraZeneca, with an upfront payment of $1.2 billion, and an $8.85 billion deal between Innovent Biologics and Eli Lilly, featuring an upfront payment of $0.35 billion [1] - Since 2026, the total upfront payment scale for innovative drug BD collaborations has surpassed the highest quarterly level of 2025, with total transaction amounts reaching $33.28 billion, indicating a rapid trend of industry expansion [1] - Leading companies have provided strong earnings forecasts, with Innovent Biologics, Rongchang Biologics, and Junshi Biosciences projecting revenues of approximately $11 billion, $3.25 billion, and $2.5 billion for 2025, reflecting year-on-year growth rates of 45%, 89%, and 32% respectively, which supports a robust fundamental outlook for the sector [1] Group 2 - The Hang Seng Hong Kong Stock Connect Innovative Drug Index is one of the first ETFs to achieve a "purity" of 100%, accurately aggregating leading companies in the Hong Kong innovative drug sector [2] - The CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index selects 50 larger market capitalization companies from the pharmaceutical and health industry within the Hong Kong Stock Connect, covering areas such as innovative drugs and medical devices [2] - Investors can track the development opportunities in the pharmaceutical industry through products like the E Fund Hong Kong Stock Connect Innovative Drug ETF (159316) and the E Fund Hong Kong Stock Connect Pharmaceutical ETF (513200) [2]